ArticlePediatric endocrinology reviews : PER2017
Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017.
Article in Pediatric endocrinology reviews : PER, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Steroid hormone antagonism affords vascular protection in a mouse model of vascular Ehlers-Danlos syndrome.JCI insight · 2026Article
- Peripheral precocious puberty in girls with McCune-Albright syndrome: a case series.Archives of endocrinology and metabolism · 2025Article
- A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience.International journal of transgender health · 2024Article
- Precocious Puberty.Indian journal of pediatrics · 2023Review
- Drug-Induced Podocytopathies: Report of Four Cases and Review of the Literature.Life (Basel, Switzerland) · 2023Review
- Precocious puberty in a child: A rare cause and review of literature.Journal of family medicine and primary care · 2022Article
- Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.Frontiers in endocrinology · 2021Review
- Delayed Diagnosis of McCune-Albright Syndrome.Case reports in genetics · 2021Article
- Comparing Machine Learning Models for Aromatase (P450 19A1).Environmental science & technology · 2020Article
- Auxological and Endocrinological Features in Children With McCune Albright Syndrome: A Review.Frontiers in endocrinology · 2020Review
- Phenotypic testicular abnormalities and pubertal development in boys with McCune-Albright syndrome.Italian journal of pediatrics · 2018Review
- Tamoxifen therapy in a murine model of myotubular myopathy.Nature communications · 2018Article
- Peculiarities of Precocious Puberty in Boys and Girls With McCune-Albright Syndrome.Frontiers in endocrinology · 2018Review
- Normal Adult Height in an Untreated Boy With McCune-Albright Syndrome Presenting With Precocious Puberty.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The most common endocrinopathy associated with McCune-Albright Syndrome (MAS) is peripheral precocious puberty (PP) which occurs far more often in girls than in boys. We will discuss the latest advancements in the treatment of precocious puberty in MAS that have been achieved during the past 10 years. However, due to the rarity of the condition and the heterogeneity of the disease, research in this field is limited particularly in regards to treatment in boys. In girls, a period of watchful waiting is recommended prior to initiating therapy due to extreme variability in the clinical course. This article will review in detail current pharmacologic treatment in girls, which typically consists of either inhibiting estrogen production or blocking estrogen action at the level of the end-organ. The two treatments with the most evidence at this time are Tamoxifen (which is an estrogen receptor modulator) and Letrozole (which is a 3rd generation aromatase inhibitor). This article will also review the current treatment strategies in boys which typically include using an androgen receptor blocker and an aromatase inhibitor. Due to the rarity of the condition, large multicenter collaborative studies are needed to further investigate efficacy and safety with the goal of establishing the gold standard for treatment of PP in children with MAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.